Live Breaking News & Updates on Indian pharmaceutical market

Stay informed with the latest breaking news from Indian pharmaceutical market on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Indian pharmaceutical market and stay connected to the pulse of your community

Steady US sales to bring a healthy quarter for pharma sector

After consistent double-digit growth in the branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits.

India , United-kingdom , British , Prabhudas-lilladher , Motilal-oswal , Sun-pharma , Aurobindo-pharma , Cipla , During-january , Healthcare-index , Alembic-pharma , Zydus-life

Indian Pharma Market Booms: 9.5% Growth in March 2024

Leading therapies like cardiac, anti-infectives, and gastro-intestinal recorded robust volume growth in MAT figures, constituting 37.5% of IPM.

Alkem-laboratories-ltd , Pfizer-ltd , Eris-lifesciences-ltd , Lupin-ltd , Cipla-ltd , Glaxosmithkline-pharmaceuticals-ltd , Sanofi-india-ltd , Abbott-india-ltd , Alembic-pharma-ltd , Mankind-pharma-ltd , Torrent-pharma-ltd

Cipla to witness surge in profit due to growth in its complex respiratory portfolio: Report

Cipla to witness surge in profit due to growth in its complex respiratory portfolio: Report
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

United-states , South-africa , India , Eli-lilly , Cipla , Price-target , Indian-pharmaceutical-market , Moving-annual-total , Earnings-before-interest , Actor-pharma , Business-today ,

Complex respiratory portfolio propels Cipla towards profitability, says Sharekhan report

A report from brokerage firm Sharekhan highlighted key factors contributing to Cipla's upward trajectory, emphasizing the company's strategic focus on complex products and the resultant impact on margins.

South-africa , Cipla , Price-target , Indian-pharmaceutical-market , Moving-annual-total , Earnings-before-interest , Actor-pharma , Earnings-per-share , Uot-complex-respiratory-portfolio , Ipla-profitability , Harekhan-report

Green shoots in Indian pharma sector: US generics, specialty drugs drive recovery, says HDFC Securities

In the US generics market, the report predicts steady growth momentum due to moderating price erosion, lesser competition, and new product launches

Sun-pharma , Zydus-lifesciences , Zydus-cadila , Reddy-laboratories-ltd , Aurobindo-pharma-ltd , Sun-pharmaceuticals , Sun-pharmaceutical-industries-ltd , Aristo-pharmaceuticals , Laurus-labs , Indian-pharmaceutical-market , Sun-pharmaceutical-industries , Aurobindo-pharma

300% rise in net profit in Q3; Analysts see exciting times ahead for this mid-cap firm

This is despite a 140% jump in the pharmaceutical firm’s stock prices over the past year

India , Dalal-street , Indian-pharmaceutical-market , Diazepam-gel , Medical-representative , Active-pharmaceutical-ingredient , Axis-securities , Lupin , Upin-shares , Upin-share-price , Upin-q3-results

Pharma market grows 9.5% in January

The Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. According to market research firm Pharmarack, a majority of the top 10 therapy areas, including cardiac, anti-infectives, and gastrointestinal, showed double-digit value growth. Respiratory, pain/analgesics, urology, antineoplastics, and stomatologicals also saw higher unit growth.

Uttarakhand , Uttaranchal , India , Telangana , Andhra-pradesh , Tamil-nadu , Sheetal-sapale , Indian-pharmaceutical-market , Pharmarack , Therapy-areas , Anti-infectives

We will continue to deepen our presence in segments like diabetes through product portfolio expansion: Krishnakumar Vaidyanathan, Executive Director, Eris Lifesciences

We will continue to deepen our presence in segments like diabetes through product portfolio expansion: Krishnakumar Vaidyanathan, Executive Director, Eris Lifesciences
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

India , Krishnakumar-vaidyanathan , Biocon-biologics , World-health-organization , Biocon , Eris-lifesciences-ltd , South-east-asia-region , Indian-pharmaceutical-market , Eris-lifesciences , Financial-express , Executive-director , Chief-operating-officer

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Pharmaceuticals major Mankind Pharma reported a 21 per cent year-on-year (Y-o-Y) increase in net profit, with revenue rising by 12 per cent Y-o-Y in the second quarter of the financial year 2024 (Q2FY24) in a regulatory filing lrecently.

Udaipur , Orissa , India , Sanket-koul , Rajeev-juneja , Mankind-pharma , Business-standard , Consumer-healthcare , Indian-pharmaceutical-market , Business-news , Usiness-news-india

pharmaceutical industry: Major domestic drug firms to report 8-10% revenue growth in FY24: Icra

Leading domestic pharmaceutical companies in India are predicted to see an 8-10% increase in revenue in the current fiscal year, according to rating agency Icra. The agency expects this growth to continue into FY2024, supported by price increases, new product launches, and improved healthcare services in rural and semi-urban areas.

Kozhikode , Kerala , India , Healthcare-management-analytics-programme , Offering-college , Indian-school-of-business , Healthcare-expertise , Compound-annual-growth-rate , Indian-pharmaceutical-market , Pharmaceutical-industry , Icra